BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 17404789)

  • 1. PET-CT vs. CT alone in ovarian cancer recurrence.
    Sebastian S; Lee SI; Horowitz NS; Scott JA; Fischman AJ; Simeone JF; Fuller AF; Hahn PF
    Abdom Imaging; 2008; 33(1):112-8. PubMed ID: 17404789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT.
    Kim CK; Park BK; Choi JY; Kim BG; Han H
    J Comput Assist Tomogr; 2007; 31(6):868-75. PubMed ID: 18043348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT.
    Ohno Y; Koyama H; Onishi Y; Takenaka D; Nogami M; Yoshikawa T; Matsumoto S; Kotani Y; Sugimura K
    Radiology; 2008 Aug; 248(2):643-54. PubMed ID: 18539889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer.
    Cho SM; Ha HK; Byun JY; Lee JM; Kim CJ; Nam-Koong SE; Lee JM
    AJR Am J Roentgenol; 2002 Aug; 179(2):391-5. PubMed ID: 12130439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent ovarian cancer: use of contrast-enhanced CT and PET/CT to accurately localize tumor recurrence and to predict patients' survival.
    Sala E; Kataoka M; Pandit-Taskar N; Ishill N; Mironov S; Moskowitz CS; Mironov O; Collins MA; Chi DS; Larson S; Hricak H
    Radiology; 2010 Oct; 257(1):125-34. PubMed ID: 20697116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer.
    Kim JH; Czernin J; Allen-Auerbach MS; Halpern BS; Fueger BJ; Hecht JR; Ratib O; Phelps ME; Weber WA
    J Nucl Med; 2005 Apr; 46(4):587-95. PubMed ID: 15809480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
    Thrall MM; DeLoia JA; Gallion H; Avril N
    Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
    Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy.
    Eubank WB; Mankoff DA; Schmiedl UP; Winter TC; Fisher ER; Olshen AB; Graham MM; Eary JF
    AJR Am J Roentgenol; 1998 Oct; 171(4):1103-10. PubMed ID: 9763005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
    Jadvar H; Henderson RW; Conti PS
    J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
    Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer.
    Dirisamer A; Halpern BS; Flöry D; Wolf F; Beheshti M; Mayerhoefer ME; Langsteger W
    Eur J Radiol; 2010 Feb; 73(2):294-9. PubMed ID: 19181468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence.
    Soussan M; Wartski M; Cherel P; Fourme E; Goupil A; Le Stanc E; Callet N; Alexandre J; Pecking AP; Alberini JL
    Gynecol Oncol; 2008 Jan; 108(1):160-5. PubMed ID: 17961640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of CT and 18F-FDG pet for detecting peritoneal metastasis on the preoperative evaluation for gastric carcinoma.
    Lim JS; Kim MJ; Yun MJ; Oh YT; Kim JH; Hwang HS; Park MS; Cha SW; Lee JD; Noh SH; Yoo HS; Kim KW
    Korean J Radiol; 2006; 7(4):249-56. PubMed ID: 17143028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy.
    Veit-Haibach P; Antoch G; Beyer T; Stergar H; Schleucher R; Hauth EA; Bockisch A
    Br J Radiol; 2007 Jul; 80(955):508-15. PubMed ID: 17537758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients.
    Nanni C; Rubello D; Farsad M; De Iaco P; Sansovini M; Erba P; Rampin L; Mariani G; Fanti S
    Eur J Surg Oncol; 2005 Sep; 31(7):792-7. PubMed ID: 15893908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-line (18)F-fluorodeoxyglucose positron emission tomography with computed tomography (PET/CT) in patients with carcinoma of the sinus/nasal area and orbit.
    Wild D; Eyrich GK; Ciernik IF; Stoeckli SJ; Schuknecht B; Goerres GW
    J Craniomaxillofac Surg; 2006 Jan; 34(1):9-16. PubMed ID: 16343913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence.
    Chung HH; Jo H; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
    Gynecol Oncol; 2007 Mar; 104(3):529-34. PubMed ID: 17049971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-PET for management of cervical and ovarian cancer.
    Havrilesky LJ; Kulasingam SL; Matchar DB; Myers ER
    Gynecol Oncol; 2005 Apr; 97(1):183-91. PubMed ID: 15790456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.